Thrive Health and Wellness, LLC
Has Thrive Health and Wellness, LLC received an FDA warning letter about GLP-1 drugs?
Yes. FDA issued Thrive Health and Wellness, LLC a warning letter naming tirzepatide, dated Feb 9, 2026, with the FDA subject line “Compounding Pharmacy/Adulterated Drug Products.” FDA has posted a close-out letter for that letter. openFDA also lists 8 drug recall reports for the firm naming semaglutide and tirzepatide.
FDA records in this index name Thrive Health and Wellness, LLC from May 21, 2025 to Feb 9, 2026.
- Names in FDA records
- Thrive Health and Wellness, LLC, dba Thrive Health Solutions (Colorado); Thrive Health and Wellness, LLC dba Thrive Health Solutions
- Type named in FDA records
- Compounding pharmacy
- FDA warning letters
- 1
- Drug recall reports
- 8
- Drugs named
- Semaglutide, Tirzepatide
- Latest record
- Feb 9, 2026
FDA warning letters
| Later letters FDA lists | Letter | |||
|---|---|---|---|---|
| Feb 9, 2026 | Compounding Pharmacy/Adulterated Drug Products | Tirzepatide | Close-out letter, Aug 6, 2026 | fda.gov |
A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.
FDA’s summary excerpts
- Feb 9, 2026: … that you repackage, such as NAD+ 50 mg/mL and MEGALean ( Tirzepatide /Cyanocobalamin) Injections 10mg/20mg/mL. 2 These … you repackage, such as NAD+ 50 mg/mL and MEGALean ( Tirzepatide /Cyanocobalamin) Injections 10mg/20mg/mL, are … you repackage, such as NAD+ 50 mg/mL and MEGALean ( Tirzepatide /Cyanocobalamin) Injections 10mg/20mg/mL, are not … Full letter
Drug recalls
| Record | |||||
|---|---|---|---|---|---|
| May 21, 2025 | Semaglutide, 5 mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112 | Lack of Assurance of Sterility | Class II | Ongoing | D-0480-2025 |
| May 21, 2025 | Semaglutide, 2.5 mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112 | Lack of Assurance of Sterility | Class II | Ongoing | D-0479-2025 |
| May 21, 2025 | Semaglutide/Cyanocobalamin Injectable, 5mg/1mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112 | Lack of Assurance of Sterility | Class II | Ongoing | D-0481-2025 |
| May 21, 2025 | Tirzepatide Injections, 30mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112 | Lack of Assurance of Sterility | Class II | Ongoing | D-0484-2025 |
| May 21, 2025 | Tirzepatide/Cyanocobalamin Injectable, 15mg/1mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112 | Lack of Assurance of Sterility | Class II | Ongoing | D-0485-2025 |
| May 21, 2025 | Tirzepatide Injections, 10mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112 | Lack of Assurance of Sterility | Class II | Ongoing | D-0482-2025 |
| May 21, 2025 | Tirzepatide/Cyanocobalamin Injectable, 30mg/1mg/mL (15mg/0.5mg/0.5mL), pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewo... | Lack of Assurance of Sterility | Class II | Ongoing | D-0486-2025 |
| May 21, 2025 | Tirzepatide Injections, 20mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112 | Lack of Assurance of Sterility | Class II | Ongoing | D-0483-2025 |
FDA compounding inspections and actions
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists one facility under this exact legal name. These entries cover all of the facility’s compounding, not only GLP-1 drugs.
Thrive Health and Wellness, LLC, dba Thrive Health Solutions, Englewood, CO (503A)
2 listed actions, including 1 Form 483 and 1 warning letter (2025 to 2026).
| Document | |||
|---|---|---|---|
| Feb 9, 2026 | Warning letter | Warning Letter (02/09/2026) | fda.gov |
| Apr 3, 2025 | Form 483 | 483 issued 04/03/2025 | fda.gov |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.
Pharmacy pages with the same legal name, built from FDA’s 503B list and compounding inspections and actions page: Thrive Health Solutions (Thrive Health and Wellness, LLC), Englewood, CO.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA warning letter, Feb 9, 2026
- openFDA drug recall enforcement reports
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA warning letters (fda.gov full-text search)
Records last pulled Nov 15, 2026. Every entry links to the original public record.